海辰药业(300584) - 2024 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2024 was ¥104,561,855.22, a decrease of 10.78% compared to ¥117,201,090.18 in the same period last year[5] - Net profit attributable to shareholders increased by 9.37% to ¥13,357,813.44 from ¥12,213,813.89 year-on-year[5] - The company achieved operating revenue of CNY 104,561,855.22, a year-on-year decrease of 10.78%[12] - Net profit attributable to the listed company was CNY 13,357,813.44, an increase of 9.37% year-on-year[12] - Net profit for Q1 2024 reached CNY 13,357,813.44, an increase of 9.4% from CNY 12,213,813.89 in Q1 2023[19] Earnings Per Share - Basic and diluted earnings per share rose by 9.33% to ¥0.1113 from ¥0.1018 in the same period last year[5] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.1113, compared to CNY 0.1018 in Q1 2023[20] Cash Flow - The net cash flow from operating activities significantly dropped by 84.14%, amounting to ¥4,680,974.46 compared to ¥29,506,108.77 in the previous year[5] - The net cash flow from operating activities for the current period is ¥4,680,974.46, a decrease of 84.2% compared to ¥29,506,108.77 in the previous period[23] - Cash inflow from operating activities totaled ¥110,901,566.65, down 21.5% from ¥141,311,878.19 in the previous period[23] - Cash outflow from operating activities was ¥106,220,592.19, a decrease of 5.0% compared to ¥111,805,769.42 in the previous period[23] - The net cash flow from investing activities is -¥29,319,647.03, an improvement from -¥53,605,687.16 in the previous period[23] - Cash inflow from financing activities was ¥30,000,000.00, down 38.8% from ¥49,000,000.00 in the previous period[23] - The net cash flow from financing activities is -¥2,302,894.43, a significant decline compared to ¥21,493,951.38 in the previous period[23] - The ending balance of cash and cash equivalents is ¥19,874,244.44, a decrease from ¥92,465,697.80 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,411,909,020.32, reflecting a slight increase of 0.22% from ¥1,408,864,380.40 at the end of the previous year[5] - Total liabilities decreased to CNY 411,047,921.63 from CNY 421,368,242.18 year-over-year[16] - Non-current assets totaled CNY 1,058,467,056.30, an increase from CNY 1,031,568,551.09 in Q1 2023[16] Research and Development - Research and development expenses surged by 80.20% to ¥5,429,812.44, indicating increased investment in innovation[8] - Research and development expenses increased to CNY 5,429,812.44, up 80.5% from CNY 3,013,143.82 in the previous year[19] Sales Performance - Sales of the main product, rivaroxaban tablets, increased by 56.32% in volume and 53.88% in sales amount compared to the same period last year[14] - Sales of the injection of landiolol hydrochloride reached CNY 6,075,000, with a volume increase of 28.46% year-on-year[14] - The company reported a significant increase in sales of cefmetazole injection, with a volume increase of 6680.00% year-on-year[14] Shareholder Information - The largest shareholder, Mr. Cao Yuping, holds 42.08% of the shares, while the second-largest shareholder, Ms. Jiang Xiaoqin, holds 9.98%[10] Other Financial Metrics - The weighted average return on equity slightly improved to 1.34% from 1.28% year-on-year[5] - The company recorded a total of ¥39,253.47 in government subsidies related to its normal business operations[6] - Total operating costs for Q1 2024 were CNY 85,582,384.45, down 16.2% from CNY 102,187,516.82 in the same period last year[18] - Inventory as of the end of Q1 2024 was CNY 87,529,909.40, an increase from CNY 81,455,425.23 at the end of Q1 2023[16] - Accounts receivable stood at CNY 200,965,069.16, slightly down from CNY 206,779,467.11 at the beginning of the period[14] Employee and Tax Expenses - The company paid ¥24,165,067.57 in employee compensation, an increase of 5.7% from ¥21,925,357.04 in the previous period[23] - The company incurred tax payments of ¥17,967,780.68, up 21.4% from ¥14,841,281.98 in the previous period[23] - The company reported a cash outflow of ¥41,888,347.37 related to other operating activities, a decrease of 29.7% from ¥59,527,108.18 in the previous period[23] Strategic Focus - The company is focusing on refining sales management and adjusting product structure to improve performance[12] - Sales expenses decreased by 35.36% to ¥38,595,773.27, attributed to optimized sales strategies and improved sales personnel efficiency[8]